Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Louisiana Humira Prior Au…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy N/A

    Humira Biosimilar Coverage Overview

    Customize your policy alerts

    Sign up for all blue cross blue shield - louisiana policy alerts

    Know when blue cross blue shield - louisiana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes Louisiana Blue commercial formulary positioning, prior authorization expectations, preferred adalimumab biosimilars list and basic biosimilar attributes and substitution rules for Humira and its biosimilars for Louisiana Blue and HMO Louisiana commercial members.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHumira Biosimilar Coverage Overview
    Policy CodePolicy N/A
    Change TypeInformational
    Effective Date
    Next Review Date
    Key ActionSubmit a prior authorization request for all new adalimumab prescriptions for clinical review; existing approved authorizations for Humira cover switching to preferred biosimilars.
    SourceLink
    POLICY UPDATE CHANGES

    No material changes to clinical coverage or policy content.

    PreferredFormulary status
    Louisiana commercialScope

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Interchangeable allowedSubstitution policy

    Humira (adalimumab) biosimilar coverage overview

    This overview applies to Louisiana Blue and HMO Louisiana commercial members and describes formulary positioning, prior authorization expectations, preferred adalimumab biosimilars, and basic biosimilar attributes and substitution rules for Humira and its biosimilars.

    Humira (adalimumab) is preferred on all Louisiana Blue and HMO Louisiana commercial formularies. The guide highlights preferred biosimilar options (including product attributes such as concentration and citrate-free formulation), interchangeability status, and program details such as Quallent products being available at $0 out-of-pocket when filled through Accredo Specialty Pharmacy subject to copay program eligibility.

    Prior authorization: All new adalimumab prescriptions require a prior authorization for clinical review. Members with an existing approved authorization for Humira do not need a new prior authorization to switch to any other preferred adalimumab product listed, and approved Humira authorizations apply to all preferred adalimumab biosimilars.

    Key facts
    Formulary statusPreferred on all commercial formularies
    ScopeApplies to Louisiana Blue and HMO Louisiana commercial members
    Substitution policyInterchangeable biosimilars may be substituted (pharmacist may substitute; Louisiana law requires patient consent and prescriber notification within 5 business days)
    Policy statusCURRENT

    Prior authorization and substitution rules

    Prior Authorization Requirements

    Prior authorization rules and switching notes for adalimumab products:

    ALL of the following

    • All new adalimumab prescriptions require a prior authorization request for clinical review
    • Switching between preferred products

      • Members with an approved authorization for Humira do not require a new prior authorization to switch to any other preferred adalimumab product listed
      • Approved prior authorizations for Humira will apply to all preferred adalimumab biosimilars
    ref():b1_0?;ref?b1_0?b1_0;ref b1_0;ref b1_0;ref b1_0;ref b1_0;ref b1_0;ref b1_0;ref b1_0?b1_0;ref b1_0?b1_0?b1_0?b1_0?b1_0;ref b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0

    What providers and pharmacists must do

    Prior Authorization

    Prior authorization required for new prescriptions

    Submit a prior authorization request for all new adalimumab prescriptions for clinical review; existing approved authorizations for Humira cover switching to preferred biosimilars. Members with an approved authorization for Humira do not require a new prior authorization to switch to any other preferred adalimumab product listed. Approved prior authorizations for Humira will apply to all preferred adalimumab biosimilars.

    Documentation Required

    Pharmacy substitution and notification (Louisiana law)

    If an interchangeable biosimilar is substituted at the pharmacy, the pharmacist must obtain the patient's consent and notify the prescriber within 5 business days as required by Louisiana law.

    Biosimilar definitions and formulation attributes

    Biosimilars are biological products highly similar to an FDA-approved reference product with no clinically meaningful differences in safety, efficacy, purity, or potency.

    Biosimilar: A biological product highly similar to an FDA-approved reference product with no clinically meaningful differences in safety, efficacy, purity and potency.

    Interchangeable biosimilar: A biosimilar that meets additional requirements allowing pharmacy-level substitution for the reference product; Louisiana law requires the patient's consent and that the pharmacist notify the prescriber within 5 business days of the dispense date.

    Document changes and review dates

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyHumira Biosimilar Coverage Overview
    Policy CodePolicy N/A
    Change TypeInformational
    Effective Date
    Next Review Date
    Key ActionSubmit a prior authorization request for all new adalimumab prescriptions for clinical review; existing approved authorizations for Humira cover switching to preferred biosimilars.
    SourceLink
    On This Page
    Humira (adalimumab) biosimilar coverage overviewPrior authorization and substitution rulesWhat providers and pharmacists must doBiosimilar definitions and formulation attributesDocument changes and review dates
    title___?b1_0?b1_0?b1_0?b1_0?b1_0;ref b1_0;ref b1_0;ref b1_0;ref b1_0?b1_0;ref b1_0?b1_0;ref b1_0_broken?b1_0?b1_0;title?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0?b1_0
    Billing Rule

    Zero out-of-pocket for Quallent via Accredo

    Louisiana Blue and HMO Louisiana members will receive Quallent adalimumab products at $0 out-of-pocket when filled with Accredo Specialty Pharmacy, subject to Quallent Pharmaceuticals copay program eligibility requirements. Accredo Specialty Pharmacy is owned by Express Scripts.